Aclarion’s Technology Shows Potential in Identifying Immune-Biomarkers in New Study

Aclarion, Inc. recently presented data from a new study highlighting the potential of their technology beyond surgical planning. The study investigated the use of Aclarion’s technology to identify immune-biomarkers, suggesting possible applications in diagnosing and monitoring immune-related conditions.

The research specifically explored the ability of Aclarion’s platform to detect and analyze biomarkers associated with immune responses. The findings indicate that the technology can effectively identify these biomarkers, opening avenues for potential use in the diagnosis, prognosis, and monitoring of various immune system disorders. These results suggest a broader utility for Aclarion’s technology, extending its application beyond its current focus on surgical planning.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI